Opus Genetics is trading lower, with no clear company-specific catalyst identified for its October 23 decline.

  • Shares are at $3.60, down 5.76%.
  • A report noted premarket strength without an identified catalyst, but that differs from the live price context provided.
  • The biotech sector is weaker, with XBI down 2.08% during the session amid broader risk-off sentiment. This may be contributing, but the evidence does not establish a specific cause.